PF-06291874

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C26H28F3N3O4
Molecular Weight	503.5134
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCC[C@H](OC1=CC(C)=C(N2C=C(C=N2)C(F)(F)F)C(C)=C1)C3=CC=C(C=C3)C(=O)NCCC(O)=O

InChI

InChIKey=IBDYYOQKQCCSDP-QFIPXVFZSA-N

InChI=1S/C26H28F3N3O4/c1-4-5-22(18-6-8-19(9-7-18)25(35)30-11-10-23(33)34)36-21-12-16(2)24(17(3)13-21)32-15-20(14-31-32)26(27,28)29/h6-9,12-15,22H,4-5,10-11H2,1-3H3,(H,30,35)(H,33,34)/t22-/m0/s1

HIDE SMILES / InChI

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Glucagon receptor 4 Target ID: CHEMBL1985 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23562063	Antagonist 2778		14.0 nM [Ki]

PubMed

Title	Date	PubMed
Efficacy and safety of the glucagon receptor antagonist PF-06291874: A 12-week, randomized, dose-response study in patients with type 2 diabetes mellitus on background metformin therapy.	2018 Nov	29923286

Name

Type

Language

PF-06291874

Code

English

.BETA.-ALANINE, N-(4-((1S)-1-(3,5-DIMETHYL-4-(4-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL)PHENOXY)BUTYL)BENZOYL)-

Systematic Name

English

Code System Code Type Description

CAS

1393124-08-7